Compositions and methods for inhibiting leishmania

Abstract

Compositions and methods for inhibiting Leishmaniasis using AIs are provided. Aspects provide compositions and methods for administering AIs alone or in combination with other compounds to infected hosts.

What is claimed as new and desired to be protected by Letters Patent of the United States is: 
     
         1 . A method of reducing the LDU of Leishmaniasis in a host, comprising:
 administering an AI to the host wherein the LDU of Leishmaniasis in the host of Leishmaniasis is reduced.   
     
     
         2 . The method of  claim 1 , wherein the LDU is reduced by reduced to less than about 47% of the untreated control. 
     
     
         3 . The method of  claim 1 , wherein the AI is AR-12. 
     
     
         4 . The method of  claim 1 , wherein the AI is co-administered with a second compound. 
     
     
         5 . The method of  claim 1 , wherein the second compound is selected from the group consisting of SSG, amphotericin B, pentamidine isethionate, miltefosine, ketoconazole, itraconazole, and fluconazole. 
     
     
         6 . The method of  claim 5 , wherein the resulting parasite burden is less than about 1% of the untreated control A method treating a host infected with Leishmaniasis, comprising:
 administering a daily dose of at least about 0.1 mg/kg of a AI and a second compound to the host.   
     
     
         8 . The method of claim  7 , wherein the AI is AR-12. 
     
     
         9 . The method of claim  7 , wherein the second compound is selected from the group consisting of SSG, amphotericin B, pentamidine isethionate, miltefosine, ketoconazole, itraconazole, and fluconazole. 
     
     
         10 . A composition comprising an AI, amphotericin B, and a pharmaceutically acceptable carrier. 
     
     
         11 . The composition of  claim 10 , wherein the AI is AR-12. 
     
     
         12 . The composition of  claim 11 , further comprising a compound selected from the group consisting of SSG, amphotericin B, pentamidine isethionate, miltefosine, ketoconazole, itraconazole, and fluconazole. 
     
     
         13 . A composition comprising an AI, SSG, and a pharmaceutically acceptable carrier. 
     
     
         14 . The composition of  claim 13 , wherein the AI is AR-12.